EBV-reactive KIR+ CX3CR1+ CD8+ T cells mediate liver transplantation tolerance.
KIR+ CX3CR1+ CD8+ T cells driven by EBV peptides promote liver transplant tolerance, with 20% of recipients showing potential biomarkers for tolerance.
- Why it matters: Understanding immune tolerance mechanisms can reduce reliance on immunosuppressants, lowering complications and improving long-term transplant success.
- What they did: The study combined single-cell transcriptomics, flow cytometry, and clinical trials involving 347 liver transplant patients to investigate how EBV-derived peptides influence immune regulation.
- The result: Findings reveal that these T cells suppress alloreactive CD4+ T cells via perforin and granzyme B, with their ratios potentially predicting tolerant recipients, offering new avenues for tolerance-inducing therapies.